2026 Interim Report
Filed with HKEX · Stock code 575 · · 90 pages · English and Chinese
Summary by 6ix AI
The report highlights a profit attributed to a milestone payment following regulatory approval for Senstend™ in China, despite facing various expenses and losses. Additionally, the company is advancing its digital telehealth services and continues to work on commercializing its products in key markets. The report also discusses the ongoing development of Fortacin™ and the company's strategic partnerships in various regions.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Regent Pacific Group Limited on 6ix
Earlier from Regent Pacific
Later from Regent Pacific
- Notification Letter to Registered Shareholders and Change Request Form
- Notification Letter to Non-registered Shareholders and Request Form
- Voluntary Announcement - Launch of Accrua - Deep Longevity's Consumer Digital Health Platform in the United States
- Monthly Return of Equity Issuer on Movements in Securities
- Voluntary Announcement - Revised Launch Timetable of Accrua Health - Deep Longevity's Consumer Digital Health Platform in the United States
Follow Regent Pacific into a list and get an email when it puts out news.
Follow Regent Pacific